Added to YB: 2026-01-05
Pitch date: 2026-01-01
NVO [bullish]
Novo Nordisk A/S
-25.53%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 318.12
Price Target
80.00 (-66%)
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Show full summary:
Novo Nordisk A/S: All-Out Assault?
NVO: Best obesity pure-play despite 4 guidance cuts in 2025. China/India rollouts targeting 280M patients worth $7B+ revenue at 5% share. Q1 2026 EPS est $1+ vs consensus $0.94-0.98. CagriSema/Amycretin preserve muscle mass vs fat loss, key advantage over Lilly's Zepbound. Target $60-80 vs current price.
Read full article (4 min)